# EDGAR Filing Document

**Accession Number:** 0001610618
**File Stem:** 0001378690-26-000003
**Filing Date:** 2026-1
**Character Count:** 9232
**Document Hash:** 7c6af2a0e2c0ed16eb41d38e114c4758
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001378690-26-000003.hdr.sgml**: 20260107

**ACCESSION NUMBER**: 0001378690-26-000003

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260107

**FILED AS OF DATE**: 20260107

**DATE AS OF CHANGE**: 20260107

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Schroeder Theodore R
- **CENTRAL INDEX KEY:** 0001378690

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36912
- **FILM NUMBER:** 26517093

**MAIL ADDRESS:**
- **STREET 1:** 12481 HIGH BLUFF DRIVE, SUITE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cidara Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001610618
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 461537286
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 6310 NANCY RIDGE DRIVE
- **STREET 2:** SUITE 101
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 858-752-6170

**MAIL ADDRESS:**
- **STREET 1:** 6310 NANCY RIDGE DRIVE
- **STREET 2:** SUITE 101
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** K2 THERAPEUTICS, INC.
- **DATE OF NAME CHANGE:** 20140611

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[x] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Schroeder Theodore R<br><sub>(Last) (First) (Middle)</sub><br>C/O CIDARA THERAPEUTICS, INC.<br>6310 NANCY RIDGE DRIVE SUITE 101<br><sub>(Street)</sub><br>SAN DIEGO, CA 92121<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-01-07 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Cidara Therapeutics, Inc. [ CDTX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (right to buy) | 204.40<sup>(1)</sup> | 2026-01-07 |  | D |  |  | 450<sup>(1)</sup> | <sup>(2)(3)</sup> | 2026-06-21 | Common Stock | 450 | <sup>(2)(3)</sup> | 0 | D |  |
| Stock Option (right to buy) | 138<sup>(1)</sup> | 2026-01-07 |  | D |  |  | 550<sup>(1)</sup> | <sup>(2)(3)</sup> | 2027-06-21 | Common Stock | 550 | <sup>(2)(3)</sup> | 0 | D |  |
| Stock Option (right to buy) | 106<sup>(1)</sup> | 2026-01-07 |  | D |  |  | 550<sup>(1)</sup> | <sup>(2)(3)</sup> | 2028-06-12 | Common Stock | 550 | <sup>(2)(3)</sup> | 0 | D |  |
| Stock Option (right to buy) | 32<sup>(1)</sup> | 2026-01-07 |  | D |  |  | 550<sup>(1)</sup> | <sup>(2)(3)</sup> | 2029-06-16 | Common Stock | 550 | <sup>(2)(3)</sup> | 0 | D |  |
| Stock Option (right to buy) | 79.40<sup>(1)</sup> | 2026-01-07 |  | D |  |  | 875<sup>(1)</sup> | <sup>(2)(3)</sup> | 2030-06-24 | Common Stock | 875 | <sup>(2)(3)</sup> | 0 | D |  |
| Stock Option (right to buy) | 38.40<sup>(1)</sup> | 2026-01-07 |  | D |  |  | 875<sup>(1)</sup> | <sup>(2)(3)</sup> | 2031-06-22 | Common Stock | 875 | <sup>(2)(3)</sup> | 0 | D |  |
| Stock Option (right to buy) | 10.60<sup>(1)</sup> | 2026-01-07 |  | D |  |  | 1400<sup>(1)</sup> | <sup>(2)(3)</sup> | 2032-06-21 | Common Stock | 1400 | <sup>(2)(3)</sup> | 0 | D |  |
| Stock Option (right to buy) | 23.40<sup>(1)</sup> | 2026-01-07 |  | D |  |  | 2125<sup>(1)</sup> | <sup>(2)(3)</sup> | 2033-06-21 | Common Stock | 2125 | <sup>(2)(3)</sup> | 0 | D |  |
| Stock Option (right to buy) | $12.64 | 2026-01-07 |  | D |  |  | 2125 | <sup>(2)(3)</sup> | 2034-07-17 | Common Stock | 2125 | <sup>(2)(3)</sup> | 0 | D |  |
| Stock Option (right to buy) | $22.81 | 2026-01-07 |  | D |  |  | 20500 | <sup>(2)(3)</sup> | 2034-12-16 | Common Stock | 20500 | <sup>(2)(3)</sup> | 0 | D |  |
| Stock Option (right to buy) | $21.31 | 2026-01-07 |  | D |  |  | 11100 | <sup>(2)(3)</sup> | 2035-06-17 | Common Stock | 11100 | <sup>(2)(3)</sup> | 0 | D |  |

---

### Footnotes:

(1) The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024.

(2) Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger").

(3) As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option.

**Signature:** /s/ Shane Ward, Attorney-in-Fact  
**Date:** 2026-01-07

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**